Clinical Trials
8 trialsNCT02912572 2025-07-10
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04672460 2024-09-25
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT03330405 2023-10-13
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Pfizer
Phase 1/2 Terminated
NCT04598321 2023-10-12
BrUOG 390: Neoadjuvant Treatment With Talazoparib
Brown University
Phase 1 Terminated
NCT03642132 2023-04-06
JAVELIN OVARIAN PARP100
Pfizer
Phase 3 Terminated
NCT01989546 2021-02-23
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02326844 2020-08-18
BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01286987 2019-01-10
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
Pfizer
Phase 1 Completed